ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologics"

  • Abstract Number: 937 • 2019 ACR/ARP Annual Meeting

    Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study

    Désirée van der Heijde1, Lianne Gensler 2, Atul Deodhar 3, Xenofon Baraliakos 4, Denis Poddubnyy 5, Alan Kivitz 6, Marga Oortgiesen 7, Dominique Baeten 8, Nadine Goldammer 9, Jason Coarse 7, MK Farmer 7 and Maxime Dougados 10, 1Leiden University Medical Center, Leiden, Netherlands, 2University San Francisco California, San Francisco, CA, 3Oregon Health & Science University, Portland, OR, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, 6Altoona Center for Clinical Research, Duncansville, PA, 7UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 8UCB Pharma, Brussels, Belgium, Brussels, 9UCB Pharma, Monheim, Germany, Monheim, Germany, 10Cochin Hospital, Paris, France

    Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…
  • Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting

    Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis

    Takeshi Shoda1, Tohru Takeuchi 2, Takuya Kotani 2, Koji Nagai 2, Kennichiro Hata 2, Shigeki Makino 2 and Shigeki Arawaka 2, 1Yodogawa christian hospital / Osaka medical college, Osaka, Japan, 2Osaka medical college, Osaka, Japan

    Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…
  • Abstract Number: 1381 • 2019 ACR/ARP Annual Meeting

    High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis

    Jun Inamo1, Yuko Kaneko 2, Jun Kikuchi 3 and Tsutomu Takeuchi 4, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 4Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Abatacept (ABT) is a soluble fusion protein, which links cytotoxic T-lymphocyte-associated protein 4 to the modified Fc portion of IgG1. Seropositivity and a shorter…
  • Abstract Number: 2346 • 2019 ACR/ARP Annual Meeting

    Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors

    Karina Bonfiglioli1, Márcio Sawamura 2, Renato Nakagawa 3, Fábio Arimura 3, Diana Rangel 3, Cleonice Bueno 4, Ana Cristina de Medeiros Ribeiro 1, Carlos Carvalho 3, Eloisa Bonfa 5, Ronaldo Kairalla 3 and Leticia Kawano-Dourado 6, 1Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 2Division of Radiology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Br, Sao Paulo, Sao Paulo, Brazil, 3Pulmonary Division, Heart Institute (InCor)- Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, 5Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, 6University of Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: A wide spectrum of interstitial lung abnormalities (ILA) occurs in patients with rheumatoid arthritis (RA). This study characterized ILA in large single-center cohort, including…
  • Abstract Number: 1399 • 2019 ACR/ARP Annual Meeting

    Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset

    Paul Bird1, Geoffrey Littlejohn 2, Belinda Butcher 3, Tegan Smith 4, Candida da Fonseca Pereira 5, David Witcombe 5 and Hedley Griffiths 6, 1Optimus Research, Kogarah, New South Wales, Australia, 2Monash Rheumatology, Clayton, Victoria, Australia, 3WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, 4OPAL Rheumatology Ltd, Sydney, New South Wales, Australia, 5Pfizer Australia, Sydney, New South Wales, Australia, 6Barwon Rheumatology Service, Geelong, Victoria, Australia

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Limited data from large real-world patient populations exist to describe…
  • Abstract Number: 2371 • 2019 ACR/ARP Annual Meeting

    Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database

    Raphaèle Seror1, Alexandre Lafourcade 2, yann De Rycke 2, Bruno Fautrel 3, Xavier Mariette 4 and Florence Tubach 5, 1Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, 2Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, 3Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France

    Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies associated with the different classes of biologics in RA patients.Methods: We conducted…
  • Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting

    Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits

    Lynn Price1, Phil Pouliot 1 and Lauren Schmitt 1, 1Spherix Global Insights, Exton, PA

    Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…
  • Abstract Number: 2372 • 2019 ACR/ARP Annual Meeting

    Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry

    Joel Kremer1, Clifton Bingham 2, Laura Cappelli 2, Jeffrey Greenberg 3, Jamie Geier 4, Ann Madsen 4, Connie Chen 4, Alina Onofrei 5, Christine Barr 5, Dimitrios Pappas 6, Heather Litman 5, Kimberly Dandreo 5, Andrea Shapiro 7, Carol Connell 8 and Arthur Kavanaugh 9, 1Albany Medical College, Albany, NY, 2Johns Hopkins University, Baltimore, MD, 3Corrona, LLC; NYU School of Medicine, Waltham, MA, 4Pfizer Inc, New York, NY, 5Corrona, LLC, Waltham, MA, 6Columbia University, New York, NY, 7Pfizer Inc, Peapack, NJ, 8Pfizer Inc, Groton, CT, 9University of California, San Diego School of Medicine, La Jolla, CA

    Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Real‑world data (RWD) complement clinical trial data in assessing long-term safety. We evaluated…
  • Abstract Number: 1498 • 2019 ACR/ARP Annual Meeting

    A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions

    Tien Nguyen1, Melvin Churchill 2, Robert Levin 3, Guillermo Valenzuela 4, Joseph Merola 5, Alexis Ogdie 6, Ana-Maria Orbai 7, Jose Scher 8, Arthur Kavanaugh 9, Shital Agawane 10, Farid Kianifard 11, Chauncy Rollins 11 and Olivier Chambenoit 11, 1Department of Dermatology, University of California, Irvine, Irvine, CA, 2Arthritis Center of Nebraska, Lincoln, NE, 3Clinical Research of West Florida, Inc and University of South Florida, Clearwater/Tampa, FL, 4Integral Rheumatology & Immunology Specialists, Plantation, FL, 5Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 6Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 7Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 8Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, 9University of California, San Diego School of Medicine, La Jolla, CA, 10Novartis Healthcare Pvt Ltd, Hyderabad, India, 11Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine…
  • Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting

    Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry

    Dimitrios Pappas1, Taylor Blachley 2, Steve Zlotnick 3, Jennie Best 3, Kelechi Emeanuru 2 and Joel Kremer 4, 1Columbia University, New York, NY, 2Corrona, LLC, Waltham, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY

    Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
  • Abstract Number: 1504 • 2019 ACR/ARP Annual Meeting

    Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years

    Helena Marzo-Ortega1, Corinne Miceli-Richard 2, Sonja Gill 3, Marina Magrey 4, Paula Machado 5, Abhijit Shete 6, Jianyuan Wang 6, Susanne Rohrer 6 and Atul Deodhar 7, 1NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, 2Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 3412 – 3075 Hospital Gate, Oakville, Canada, 4Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Novartis Pharma AG, Basel, Switzerland, 7Oregon Health & Science University, Portland, OR

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60%…
  • Abstract Number: 2399 • 2019 ACR/ARP Annual Meeting

    Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis

    Carlos Sánchez-Piedra1, María Colazo 2, Rosa Roselló 3, Cristina Campos 4, P. Vela 5, Cristina Bohorquez 6, Carolina Pérez-García 7, Manuel Pombo-Suarez 8, Carlos Fernández-López 9, Dolores Ruiz-Montesinos 10, Fernando Alonso 11, Federico Diaz-Gonzalez 12 and Juan Jesús Gómez-Reino 13, 1Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 2Hospital de Burgos, Burgos, 3Hospital San Jorge, Huesca, 4Hospital General de Valencia, Valencia, 5Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, 6Universitary Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcala de Henares, Spain, 7Rheumatology, Hospital del Mar, Barcelona, Catalonia, Spain, 8Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 9Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, 10Hospital Virgen Macarena, Sevilla, 11Unidad Investigación SER, Madrid, Spain, 12Hospital de Canarias, Tenerife, 13Hospital de Santiago, Santiago de Compostela

    Background/Purpose: During the past 15 years, advancements in the understanding of the safety and effectiveness, as well as the expanding access and availability of biologic…
  • Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting

    Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials

    Marina Magrey1, Victoria Navarro-Compán 2, Sandra Garces 3, Xenofon Baraliakos 4, David Sandoval 3, Jeffrey Lisse 3, Silvia Santisteban 3, David Adams 3, Fangyi Zhao 3 and Robert Inman 5, 1Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, 2University Hospital La Paz, IdiPaz, Madrid, Spain, 3Eli Lilly and Company, Indianapolis, IN, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5University of Toronto, University Health Network, Toronto, ON, Canada

    Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
  • Abstract Number: 2505 • 2019 ACR/ARP Annual Meeting

    Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina

    Luciano Fernando Lo Giudice1, Maria Laura Acosta Felquer 1, Luis Daniel Mazzuoccolo 2, Maria Laura Galimberti 2 and Enrique Soriano 3, 1Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 2Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in…
  • Abstract Number: 1520 • 2019 ACR/ARP Annual Meeting

    Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status

    Steven Feldman 1, Jingchuan Zhang2, Diane Martinez 3, Lorena Lopez-Gonzalez 3, Elizabeth Holt Marchlewicz 3, George Shrady 3, Alan Mendelsohn 4 and Yang zhao 5, 1Wake Forest Baptist Health, Winston-Salem, NC, 2Sun Pharmaceutical Industries, Princeton, NJ, 3IBM Watson Health, Washington, DC, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 5Sun Pharmaceutical Industries, Princeton

    Background/Purpose: Long-term real-world treatment patterns of psoriasis patients are not well characterized, especially those with comorbid psoriatic arthritis (PsA). This study examined the treatment patterns…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology